{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cao Z"],"funding":["Central South University"],"pagination":["9013283"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7661137"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2020"],"pubmed_abstract":["<h4>Objective</h4>Most guidelines recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of osteoarthritis (OA), but the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti-IL-1<i>α</i>/<i>β</i> dual variable domain immunoglobulin that can simultaneously bind and inhibit IL-1<i>α</i> and IL-1<i>β</i> to relieve the pain and dysfunction symptoms. We conducted this network meta-analysis to comprehensively compare the clinical efficacy and safety of lutikizumab with other drugs recommended by guidelines.<h4>Methods</h4>We conducted a Bayesian network and conventional meta-analyses to compare the efficacy and safety of lutikizumab with other traditional drugs. All eligible randomized cl"],"journal":["BioMed research international"],"pubmed_title":["Is Lutikizumab, an Anti-Interleukin-1&lt;i&gt;α&lt;/i&gt;/&lt;i&gt;β&lt;/i&gt; Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis."],"pmcid":["PMC7661137"],"funding_grant_id":["GCX20190879Y"],"pubmed_authors":["Li Y","Cao Z","Long Z","Hu X","Dou P","Wu R","Wang W","Wu T","Aili D","Jie S","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Is Lutikizumab, an Anti-Interleukin-1&lt;i&gt;α&lt;/i&gt;/&lt;i&gt;β&lt;/i&gt; Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis.","description":"<h4>Objective</h4>Most guidelines recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of osteoarthritis (OA), but the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti-IL-1<i>α</i>/<i>β</i> dual variable domain immunoglobulin that can simultaneously bind and inhibit IL-1<i>α</i> and IL-1<i>β</i> to relieve the pain and dysfunction symptoms. We conducted this network meta-analysis to comprehensively compare the clinical efficacy and safety of lutikizumab with other drugs recommended by guidelines.<h4>Methods</h4>We conducted a Bayesian network and conventional meta-analyses to compare the efficacy and safety of lutikizumab with other traditional drugs. All eligible randomized cl","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2026-07-09T10:43:59.176Z","creation":"2025-05-29T19:36:58.506Z"},"accession":"S-EPMC7661137","cross_references":{"pubmed":["33204726"],"doi":["10.1155/2020/9013283"]}}